A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
In a cell-based screen of novel anticancer agents, the hit compound 1a which bears a pyrazolo [3,4-d]pyrimidine scaffold exhibited high inhibitory activity against a panel of four different types of tumor cell lines. In particular, the IC 50 for A549 cells was 2.24 µM, compared with an IC 50 of 9.20 µM for doxorubicin, the positive control. Four synthetic routes of the key intermediate 3 of 1a were explored and 1a was prepared via route D on the gram scale for further research. Two analogs ofdoi:10.3390/molecules161210685 pmid:22186955 fatcat:cp2kzndlx5c6bcxxmmqb5ltfxe